Mvasi gets Canadian approval
Executive Summary
Amgen has moved closer to introducing in Canada its Mvasi (bevacizumab) biosimilar rival to Genentech’s Avastin, after obtaining approval from Health Canada for 100mg/4ml and 400mg/16ml single-use vials. Stating that Mvasi’s indications were granted on the “basis of similarity” between the biosimilar and Avastin, a product monograph released by Health Canada noted that Mvasi will be used to treat metastatic colorectal cancer and locally advanced, metastatic or recurrent non-small cell lung cancer.